Alpha Teknova Stock Price, News & Analysis

Teknova (Nasdaq: TKNO) announced it will report Q1 financial results for the period ending March 31, 2023, on May 10, 2023, after market close. A conference call and webcast will follow at 5:00 p.m. ET on the same day, accessible via the company's Investor Relations page. Founded in 1996 and headquartered in Hollister, California, Teknova specializes in producing critical reagents for life sciences, supporting cell and gene therapy, molecular diagnostics, and synthetic biology. The company offers customizable solutions for various workflows, emphasizing fast turnaround of high-quality products, which are vital for therapy discovery and development.

Alpha Teknova, Inc. (TKNO) reported a 12% increase in total revenue for 2022, reaching $41.4 million. The company has launched a new manufacturing facility, enhancing its production capabilities. For 2023, Teknova anticipates revenue between $42 million and $46 million, with expectations of significant growth in Clinical Solutions.

However, the company faced a net loss of $47.5 million for 2022, primarily due to non-cash impairment charges totaling $20.8 million. Operating expenses surged to $67.1 million, reflecting increased costs.

Alpha Teknova and Sartorius BIA Separations announced a collaboration to enhance AAV (adeno-associated virus) purification for gene therapy, optimizing recovery of viral particles. This partnership utilizes Sartorius’ proprietary AAV platform and Teknova’s custom buffer formulations, resulting in a newly developed screening kit aimed at increasing purity and consistency during purification processes. The collaboration is expected to accelerate workflow for gene therapy companies, aiding in the discovery of novel therapies. Both companies will continue to develop data demonstrating improvements in AAV purification through their combined efforts.

Alpha Teknova (Nasdaq: TKNO) announced it will report its financial results for Q4 and full year 2022 on March 15, 2023, after market close. The company specializes in critical reagents for life sciences, enhancing the development of therapies and diagnostics. A webcast and conference call will follow at 5:00 p.m. ET, accessible through their Investor Relations page. The event's replay will be available two hours post-event.

Alpha Teknova, Inc. (Nasdaq: TKNO) announced its participation in two upcoming investor conferences: the BTIG Snowbird Conference from February 14-16, 2023, in Snowbird, UT, and the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, MA. During the Cowen event, CEO Stephen Gunstream and CFO Matt Lowell will present highlights on the company’s product portfolio, market trends, and growth opportunities on March 8 at 2:10 p.m. EST. Interested investors can access a live audio webcast from the Investor Relations section of Teknova's website, available for 90 days post-event.